相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer
Wentao Zhang et al.
TRANSLATIONAL ONCOLOGY (2019)
Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder
Michael Owyong et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder
Bo Wang et al.
CANCER SCIENCE (2019)
Prognostic value of PD-L1 expression in patients with pancreatic cancer A PRISMA-compliant meta-analysis
Ying Hu et al.
MEDICINE (2019)
Patient-Reported Outcomes with PD-1/PD-L1 Inhibitors for Advanced Cancer: A Meta-Analysis
Tomohiro F. Nishuima et al.
ONCOLOGIST (2019)
Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis
Zefeng Shen et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2019)
The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis
Guangzhi Ma et al.
CLINICA CHIMICA ACTA (2018)
Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients
Renate Pichler et al.
CLINICAL GENITOURINARY CANCER (2018)
The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis
He-Li Gao et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2018)
Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
Jing-Hua Li et al.
FRONTIERS IN IMMUNOLOGY (2018)
The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis
Shu Zhao et al.
CANCER BIOLOGY & MEDICINE (2018)
Expression of B7 Homolog 1 (B7H1) Is Associated with Clinicopathologic Features in Urothelial Bladder Cancer
Qingyuan Li et al.
MEDICAL SCIENCE MONITOR (2018)
Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck
Juana Maria Garcia-Pedrero et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Post-chemotherapy PD-L1 expression correlates with clinical outcomes in Japanese bladder cancer patients treated with total cystectomy
Daisuke Noro et al.
MEDICAL ONCOLOGY (2017)
Prognostic significance of PD-L1 in solid tumor An updated meta-analysis
Qianqian Wang et al.
MEDICINE (2017)
Expression of PD-L1 and prognosis in breast cancer: a meta-analysis
Minghui Zhang et al.
ONCOTARGET (2017)
PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer
Lujun Chen et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies
Susan F. Slovin
BIOMARKERS IN MEDICINE (2017)
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Jason Madore et al.
CLINICAL CANCER RESEARCH (2016)
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
Sara Gandini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
The role of PD-L1 in the radiation response and clinical outcome for bladder cancer
Chun-Te Wu et al.
SCIENTIFIC REPORTS (2016)
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2015)
PD-1-PD-L1 axis: efficient checkpoint blockade against cancer
Alessia Errico
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
Jason Madore et al.
PIGMENT CELL & MELANOMA RESEARCH (2015)
New insights into cancer immunoediting and its three component phases elimination, equilibrium and escape
Deepak Mittal et al.
CURRENT OPINION IN IMMUNOLOGY (2014)
Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder
E. Xylinas et al.
EJSO (2014)
Are studies reporting significant results more likely to be published?
Despina Koletsi et al.
AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS (2009)
Costimulatory Molecule B7-H1 on the Immune Escape of Bladder Cancer and Its Clinical Significance
Yonghua Wang et al.
JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
T-cell coregulatory molecule expression in urothelial cell carcinoma: Clinicopathologic correlations and association with survival
Stephen A. Boorjian et al.
CLINICAL CANCER RESEARCH (2008)
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
Juro Nakanishi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy
C Blank et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
分享论文
